You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDipyridamole
Accession NumberDB00975  (APRD00360)
TypeSmall Molecule
GroupsApproved
DescriptionA phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
Structure
Thumb
Synonyms
Cardoxin
Cleridium 150
Curantyl
Dipiridamol
Dipyridamine
Dipyridamolum
Dipyudamine
Dypyridamol
Persantin
External Identifiers
  • USAF GE-12
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DipyridamoleTablet25 mg/1OralCarilion Materials Management2012-02-15Not applicableUs
DipyridamoleTablet25 mg/1OralRoxane Laboratories, Inc.2012-02-15Not applicableUs
DipyridamoleTablet50 mg/1OralRoxane Laboratories, Inc.2012-02-15Not applicableUs
DipyridamoleTablet75 mg/1OralRoxane Laboratories, Inc.2012-02-15Not applicableUs
Dipyridamole 25 Tab 25mgTablet25 mgOralPro Doc Limitee1983-12-312002-08-02Canada
Dipyridamole 50 Tab 50mgTablet50 mgOralPro Doc Limitee1983-12-312002-08-02Canada
Dipyridamole 75 TabTablet75 mgOralPro Doc Limitee1984-12-312002-08-02Canada
Dipyridamole for InjectionSolution5 mgIntravenousNovopharm Limited2002-04-30Not applicableCanada
Dipyridamole Injection, USPLiquid5 mgIntravenousFresenius Kabi Canada Ltd2002-04-23Not applicableCanada
Dipyridamole-25Tablet25 mgOralPro Doc Limitee1998-08-282010-07-13Canada
Dipyridamole-50Tablet50 mgOralPro Doc Limitee1998-08-282010-07-13Canada
Dipyridamole-75Tablet75 mgOralPro Doc Limitee1998-08-282010-07-13Canada
Novo-dipiradol Sct 100mgTablet100 mgOralNovopharm Limited1991-12-312005-08-10Canada
Novo-dipiradol Tab 25mgTablet25 mgOralNovopharm Limited1989-12-312005-08-10Canada
Novo-dipiradol Tab 50mgTablet50 mgOralNovopharm Limited1989-12-312005-08-10Canada
Novo-dipiradol Tab 75mgTablet75 mgOralNovopharm Limited1989-12-312005-08-10Canada
PersantineTablet, coated50 mg/1OralBoehringer Ingelheim Pharmaceuticals, Inc.1999-06-01Not applicableUs
PersantineTablet, coated75 mg/1OralBoehringer Ingelheim Pharmaceuticals, Inc.1999-06-01Not applicableUs
PersantineSolution5 mgIntravenousBoehringer Ingelheim (Canada) Ltd Ltee1986-12-31Not applicableCanada
PersantineTablet, coated25 mg/1OralBoehringer Ingelheim Pharmaceuticals, Inc.1999-06-01Not applicableUs
Persantine Tab 100mgTablet100 mgOralBoehringer Ingelheim (Canada) Ltd Ltee1985-12-312002-07-25Canada
Persantine Tab 25mgTablet25 mgOralBoehringer Ingelheim (Canada) Ltd Ltee1962-12-312005-02-14Canada
Persantine Tab 50mgTablet50 mgOralBoehringer Ingelheim (Canada) Ltd Ltee1968-12-312011-03-03Canada
Persantine Tab 75mgTablet75 mgOralBoehringer Ingelheim (Canada) Ltd Ltee1981-12-312010-06-28Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-dipyridamole-FC Tab 25mgTablet25 mgOralApotex Inc1990-12-31Not applicableCanada
Apo-dipyridamole-FC Tab 50mgTablet50 mgOralApotex Inc1990-12-31Not applicableCanada
Apo-dipyridamole-FC Tab 75mgTablet75 mgOralApotex Inc1990-12-31Not applicableCanada
Apo-dipyridamole-SC Tab 25mgTablet25 mgOralApotex Inc1982-12-31Not applicableCanada
Apo-dipyridamole-SC Tab 50mgTablet50 mgOralApotex Inc1982-12-31Not applicableCanada
Apo-dipyridamole-SC Tab 75mgTablet75 mgOralApotex Inc1984-12-31Not applicableCanada
DipyridamoleInjection5 mg/mLIntravenousWest Ward Pharmaceutical Corp.1996-10-18Not applicableUs
DipyridamoleTablet, film coated50 mg/1OralRising Pharmaceuticals, Inc.2007-02-13Not applicableUs
DipyridamoleTablet, film coated25 mg/1OralTeva Pharmaceuticals Usa, Inc.1980-10-01Not applicableUs
DipyridamoleTablet25 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2007-07-18Not applicableUs
DipyridamoleTablet, film coated50 mg/1OralAv Pak2011-08-052016-01-15Us
DipyridamoleTablet, film coated75 mg/1OralCadila Healthcare Limited2008-05-22Not applicableUs
DipyridamoleTablet, film coated25 mg/1OralAv Kare, Inc.2007-07-082016-10-13Us
DipyridamoleTablet, film coated50 mg/1OralCardinal Health2008-10-30Not applicableUs
DipyridamoleTablet, film coated50 mg/1OralLannett Company, Inc.2008-04-23Not applicableUs
DipyridamoleTablet, film coated25 mg/1OralMajor Pharmaceuticals2008-10-30Not applicableUs
DipyridamoleTablet, film coated75 mg/1OralRising Pharmaceuticals, Inc.2007-02-13Not applicableUs
DipyridamoleTablet, film coated50 mg/1OralTeva Pharmaceuticals Usa, Inc.1982-01-01Not applicableUs
DipyridamoleTablet50 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2007-07-18Not applicableUs
DipyridamoleTablet, film coated75 mg/1OralAv Pak2011-08-052016-01-15Us
DipyridamoleTablet, film coated25 mg/1OralZydus Pharmaceuticals (USA) Inc.2008-05-22Not applicableUs
DipyridamoleTablet, film coated50 mg/1OralAv Kare, Inc.2007-07-082016-10-13Us
DipyridamoleTablet, film coated50 mg/1OralCardinal Health2011-08-05Not applicableUs
DipyridamoleTablet, film coated75 mg/1OralLannett Company, Inc.2008-04-23Not applicableUs
DipyridamoleTablet, film coated75 mg/1OralTeva Pharmaceuticals Usa, Inc.1982-01-01Not applicableUs
DipyridamoleTablet, film coated50 mg/1OralMajor Pharmaceuticals2008-10-30Not applicableUs
DipyridamoleTablet, film coated25 mg/1OralCadila Healthcare Limited2008-05-22Not applicableUs
DipyridamoleInjection, solution5 mg/mLIntravenousGeneral Injectables & Vaccines, Inc2010-09-01Not applicableUs
DipyridamoleTablet75 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2007-07-18Not applicableUs
DipyridamoleTablet, film coated50 mg/1OralZydus Pharmaceuticals (USA) Inc.2008-05-22Not applicableUs
DipyridamoleTablet, film coated75 mg/1OralAv Kare, Inc.2007-07-082016-10-13Us
DipyridamoleTablet, film coated25 mg/1OralRising Pharmaceuticals, Inc.2007-08-05Not applicableUs
DipyridamoleTablet, film coated25 mg/1OralAvera Mc Kennan Hospital2015-11-17Not applicableUs
DipyridamoleTablet, film coated50 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-01-23Not applicableUs
DipyridamoleTablet, film coated50 mg/1OralCadila Healthcare Limited2008-05-22Not applicableUs
DipyridamoleTablet, film coated75 mg/1OralA S Medication Solutions1982-01-01Not applicableUs
DipyridamoleTablet, film coated75 mg/1OralMajor Pharmaceuticals2008-10-30Not applicableUs
DipyridamoleTablet, film coated75 mg/1OralCardinal Health2008-10-30Not applicableUs
DipyridamoleTablet, film coated25 mg/1OralLannett Company, Inc.2008-04-23Not applicableUs
DipyridamoleTablet, film coated75 mg/1OralZydus Pharmaceuticals (USA) Inc.2008-05-22Not applicableUs
DipyridamoleTablet, film coated25 mg/1OralAv Pak2007-08-052016-01-15Us
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DipyridamoleSolution5 mg/mLIntravenousAnazao Health Corporation2012-05-23Not applicableUs
International Brands
NameCompany
Agileaselsei
CardoxinRafa
Cleridium 150Millot
CurantylArzneimittelwerk
PersantinNot Available
Brand mixtures
NameLabellerIngredients
AggrenoxRebel Distributors Corp.
Asasantine CapBoehringer Ingelheim (Canada) Ltd Ltee
Aspirin and DipyridamoleRoxane Laboratories, Inc.
SaltsNot Available
Categories
UNII64ALC7F90C
CAS number58-32-2
WeightAverage: 504.6256
Monoisotopic: 504.317251808
Chemical FormulaC24H40N8O4
InChI KeyIZEKFCXSFNUWAM-UHFFFAOYSA-N
InChI
InChI=1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2
IUPAC Name
2-({6-[bis(2-hydroxyethyl)amino]-4,8-bis(piperidin-1-yl)-[1,3]diazino[5,4-d]pyrimidin-2-yl}(2-hydroxyethyl)amino)ethan-1-ol
SMILES
OCCN(CCO)C1=NC2=C(N=C(N=C2N2CCCCC2)N(CCO)CCO)C(=N1)N1CCCCC1
Pharmacology
IndicationFor as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement and also used in prevention of angina.
Structured Indications
PharmacodynamicsDipyridamole, a non-nitrate coronary vasodilator that also inhibits platelet aggregation, is combined with other anticoagulant drugs, such as warfarin, to prevent thrombosis in patients with valvular or vascular disorders. Dipyridamole is also used in myocardial perfusion imaging, as an antiplatelet agent, and in combination with aspirin for stroke prophylaxis.
Mechanism of actionDipyridamole likely inhibits both adenosine deaminase and phosphodiesterase, preventing the degradation of cAMP, an inhibitor of platelet function. This elevation in cAMP blocks the release of arachidonic acid from membrane phospholipids and reduces thromboxane A2 activity. Dipyridamole also directly stimulates the release of prostacyclin, which induces adenylate cyclase activity, thereby raising the intraplatelet concentration of cAMP and further inhibiting platelet aggregation.
TargetKindPharmacological actionActionsOrganismUniProt ID
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AProteinyes
inhibitor
HumanQ9Y233 details
cGMP-specific 3',5'-cyclic phosphodiesteraseProteinyes
inhibitor
HumanO76074 details
cAMP-specific 3',5'-cyclic phosphodiesterase 4AProteinyes
inhibitor
HumanP27815 details
Adenosine deaminaseProteinyes
inhibitor
HumanP00813 details
Related Articles
Absorption70%
Volume of distribution
  • 1 to 2.5 L/kg
Protein binding99%
Metabolism

hepatic

Route of eliminationDipyridamole is metabolized in the liver to the glucuronic acid conjugate and excreted with the bile.
Half life40 minutes
Clearance
  • 2.3-3.5 mL/min/kg
ToxicityHypotension, if it occurs, is likely to be of short duration, but a vasopressor drug may be used if necessary. The oral LD50 in rats is greater than 6,000 mg/kg while in the dogs, the oral LD50 is approximately 400 mg/kg. LD50=8.4g/kg (orally in rat)
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Dipyridamole (Antiplatelet) Action PathwayDrug actionSMP00264
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Dipyridamole.Experimental
AbciximabDipyridamole may increase the anticoagulant activities of Abciximab.Approved
AcebutololDipyridamole may increase the bradycardic activities of Acebutolol.Approved
AcenocoumarolDipyridamole may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Dipyridamole.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Acetazolamide.Approved, Vet Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Acetylsalicylic acid.Approved, Vet Approved
AdenosineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Adenosine.Approved, Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Dipyridamole.Approved
AlbendazoleThe serum concentration of Dipyridamole can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Dipyridamole.Approved
AldosteroneThe serum concentration of Dipyridamole can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Dipyridamole can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Dipyridamole can be increased when it is combined with Alfentanil.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Aliskiren.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Dipyridamole.Approved, Investigational
AlprenololDipyridamole may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
AlprostadilAlprostadil may increase the anticoagulant activities of Dipyridamole.Approved, Investigational
AlteplaseDipyridamole may increase the anticoagulant activities of Alteplase.Approved
ALX-0081Dipyridamole may increase the anticoagulant activities of ALX-0081.Investigational
AmantadineThe serum concentration of Dipyridamole can be increased when it is combined with Amantadine.Approved
AmbenoniumThe therapeutic efficacy of Ambenonium can be decreased when used in combination with Dipyridamole.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Dipyridamole.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Dipyridamole.Approved
Aminohippuric acidThe serum concentration of Dipyridamole can be increased when it is combined with Aminohippuric acid.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Aminosalicylic Acid.Approved
AmiodaroneThe serum concentration of Dipyridamole can be decreased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Dipyridamole.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Dipyridamole.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Dipyridamole.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Dipyridamole can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Dipyridamole can be increased when it is combined with Amsacrine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Amyl Nitrite.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Dipyridamole.Approved
AncrodDipyridamole may increase the anticoagulant activities of Ancrod.Investigational
AnistreplaseDipyridamole may increase the anticoagulant activities of Anistreplase.Approved
Antithrombin III humanDipyridamole may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Dipyridamole may increase the bradycardic activities of Aop200704.Investigational
ApixabanThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Apixaban.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Dipyridamole.Approved
AprotininThe therapeutic efficacy of Dipyridamole can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArdeparinDipyridamole may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanDipyridamole may increase the anticoagulant activities of Argatroban.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Dipyridamole.Approved, Investigational
ArotinololDipyridamole may increase the bradycardic activities of Arotinolol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Dipyridamole.Approved, Investigational
AstaxanthinDipyridamole may increase the anticoagulant activities of Astaxanthin.Investigational
AstemizoleThe serum concentration of Dipyridamole can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Dipyridamole.Approved, Investigational
AtenololDipyridamole may increase the bradycardic activities of Atenolol.Approved
AtorvastatinThe serum concentration of Dipyridamole can be increased when it is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Dipyridamole.Approved, Investigational
AzelastineThe serum concentration of Dipyridamole can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Azilsartan medoxomil.Approved
AzithromycinThe serum concentration of Dipyridamole can be increased when it is combined with Azithromycin.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Dipyridamole.Experimental
BarbitalBarbital may increase the hypotensive activities of Dipyridamole.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Barnidipine.Approved
BatroxobinDipyridamole may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminDipyridamole may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BefunololDipyridamole may increase the bradycardic activities of Befunolol.Experimental
BemiparinDipyridamole may increase the anticoagulant activities of Bemiparin.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Dipyridamole.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Dipyridamole.Approved
BenzocaineThe serum concentration of Dipyridamole can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Dipyridamole can be increased when it is combined with Bepridil.Approved, Withdrawn
BeraprostDipyridamole may increase the anticoagulant activities of Beraprost.Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Dipyridamole.Approved, Vet Approved
BetaxololDipyridamole may increase the bradycardic activities of Betaxolol.Approved
BevantololDipyridamole may increase the bradycardic activities of Bevantolol.Approved
BiperidenThe serum concentration of Dipyridamole can be increased when it is combined with Biperiden.Approved
BisoprololDipyridamole may increase the bradycardic activities of Bisoprolol.Approved
BivalirudinDipyridamole may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Dipyridamole.Approved
BopindololDipyridamole may increase the bradycardic activities of Bopindolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Bortezomib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Dipyridamole.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dipyridamole.Approved
BretyliumThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Dipyridamole.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Dipyridamole.Approved, Investigational
BucindololDipyridamole may increase the bradycardic activities of Bucindolol.Investigational
BufuralolDipyridamole may increase the bradycardic activities of Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Dipyridamole.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Bupivacaine.Approved, Investigational
BupranololDipyridamole may increase the bradycardic activities of Bupranolol.Approved
BuprenorphineThe serum concentration of Dipyridamole can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Dipyridamole can be increased when it is combined with Buspirone.Approved, Investigational
ButylphthalideButylphthalide may increase the anticoagulant activities of Dipyridamole.Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Dipyridamole.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Dipyridamole.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Dipyridamole.Experimental
CanagliflozinThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Dipyridamole.Approved
CangrelorDipyridamole may increase the anticoagulant activities of Cangrelor.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Captopril.Approved
CarbamazepineThe serum concentration of Dipyridamole can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Carbetocin.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Dipyridamole.Approved
CarteololDipyridamole may increase the bradycardic activities of Carteolol.Approved
CarvedilolDipyridamole may increase the bradycardic activities of Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Dipyridamole can be increased when it is combined with Caspofungin.Approved
CeliprololDipyridamole may increase the bradycardic activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Dipyridamole.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Dipyridamole.Withdrawn
CertoparinDipyridamole may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe serum concentration of Dipyridamole can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Dipyridamole.Approved, Vet Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Dipyridamole.Approved, Vet Approved
ChlorpropamideThe serum concentration of Dipyridamole can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Dipyridamole can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Dipyridamole.Approved
CholesterolThe serum concentration of Dipyridamole can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Dipyridamole can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Cilnidipine.Approved
CilostazolDipyridamole may increase the anticoagulant activities of Cilostazol.Approved
CimetidineThe serum concentration of Dipyridamole can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Dipyridamole.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Dipyridamole.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Dipyridamole.Approved
Citric AcidDipyridamole may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Dipyridamole.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Clevidipine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Dipyridamole.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Clofarabine.Approved, Investigational
ClofazimineThe serum concentration of Dipyridamole can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Dipyridamole.Approved, Investigational
ClomipramineThe serum concentration of Dipyridamole can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Dipyridamole.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Dipyridamole.Approved, Nutraceutical
ClotrimazoleThe serum concentration of Dipyridamole can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Dipyridamole.Approved
CobicistatThe serum concentration of Dipyridamole can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Dipyridamole.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Dipyridamole.Approved
ColforsinThe serum concentration of Dipyridamole can be increased when it is combined with Colforsin.Experimental
CollagenaseThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Collagenase.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Dipyridamole.Approved
CoumaphosThe therapeutic efficacy of Coumaphos can be decreased when used in combination with Dipyridamole.Vet Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Dipyridamole.Approved
CyclophosphamideThe serum concentration of Dipyridamole can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Dipyridamole can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateDipyridamole may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Dipyridamole.Approved
DaclatasvirThe serum concentration of Dipyridamole can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Dipyridamole.Approved
DalteparinDipyridamole may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidDipyridamole may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapagliflozinThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Dapagliflozin.Approved
DasatinibDasatinib may increase the anticoagulant activities of Dipyridamole.Approved, Investigational
DaunorubicinThe serum concentration of Dipyridamole can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Dipyridamole.Approved
DecamethoniumThe therapeutic efficacy of Decamethonium can be decreased when used in combination with Dipyridamole.Approved
DefibrotideDipyridamole may increase the anticoagulant activities of Defibrotide.Approved, Investigational
DemecariumThe therapeutic efficacy of Demecarium can be decreased when used in combination with Dipyridamole.Approved
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Deoxycholic Acid.Approved
dersalazineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with dersalazine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Desflurane.Approved
DesipramineThe serum concentration of Dipyridamole can be increased when it is combined with Desipramine.Approved
DesirudinDipyridamole may increase the anticoagulant activities of Desirudin.Approved
DesloratadineThe serum concentration of Dipyridamole can be increased when it is combined with Desloratadine.Approved, Investigational
DesmoteplaseDipyridamole may increase the anticoagulant activities of Desmoteplase.Investigational
DexamethasoneThe serum concentration of Dipyridamole can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dipyridamole.Approved, Vet Approved
DextranDipyridamole may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Dipyridamole may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Dipyridamole may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Dipyridamole may increase the anticoagulant activities of Dextran 75.Approved
DextromethorphanThe serum concentration of Dipyridamole can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Dipyridamole.Approved, Illicit, Vet Approved
DichlorvosThe therapeutic efficacy of Dichlorvos can be decreased when used in combination with Dipyridamole.Vet Approved
DiclofenacThe serum concentration of Dipyridamole can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Diclofenamide.Approved
DicoumarolDipyridamole may increase the anticoagulant activities of Dicoumarol.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Dipyridamole.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Diflunisal.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Dipyridamole.Approved
DigoxinThe serum concentration of Dipyridamole can be decreased when it is combined with Digoxin.Approved
DihydroergotamineThe serum concentration of Dipyridamole can be increased when it is combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Dipyridamole.Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Dipyridamole.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Dinutuximab.Approved
DitazoleDipyridamole may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Dipyridamole.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Dipyridamole.Approved, Investigational, Vet Approved
DonepezilThe therapeutic efficacy of Donepezil can be decreased when used in combination with Dipyridamole.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Dipyridamole.Approved
DoxepinThe serum concentration of Dipyridamole can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Dipyridamole.Approved, Investigational
DoxorubicinThe serum concentration of Dipyridamole can be decreased when it is combined with Doxorubicin.Approved, Investigational
DronabinolThe serum concentration of Dipyridamole can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Dipyridamole can be increased when it is combined with Dronedarone.Approved
Drotrecogin alfaDipyridamole may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
DuloxetineDipyridamole may increase the orthostatic hypotensive activities of Duloxetine.Approved
EchothiophateThe therapeutic efficacy of Echothiophate can be decreased when used in combination with Dipyridamole.Approved
Edetic AcidDipyridamole may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Dipyridamole.Approved
EdrophoniumThe therapeutic efficacy of Edrophonium can be decreased when used in combination with Dipyridamole.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Efonidipine.Approved
ElbasvirThe serum concentration of Dipyridamole can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Dipyridamole.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Dipyridamole.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Enalaprilat.Approved
EnoxaparinDipyridamole may increase the anticoagulant activities of Enoxaparin.Approved
EnzalutamideThe serum concentration of Dipyridamole can be increased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Dipyridamole.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Dipyridamole.Approved
eplivanserineDipyridamole may increase the anticoagulant activities of eplivanserine.Investigational
EpoprostenolThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Dipyridamole.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Dipyridamole.Approved, Investigational
ErgonovineThe serum concentration of Dipyridamole can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Dipyridamole can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Dipyridamole.Approved, Investigational
ErythromycinThe serum concentration of Dipyridamole can be decreased when it is combined with Erythromycin.Approved, Vet Approved
EsmololDipyridamole may increase the bradycardic activities of Esmolol.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Dipyridamole.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Dipyridamole can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Dipyridamole can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Dipyridamole can be decreased when it is combined with Estrone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Dipyridamole.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Dipyridamole.Approved
Ethyl biscoumacetateDipyridamole may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtoposideThe serum concentration of Dipyridamole can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Dipyridamole can be increased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Dipyridamole.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Dipyridamole.Approved
FelodipineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Felodipine.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Fenoldopam.Approved
FentanylThe serum concentration of Dipyridamole can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Fenthion can be decreased when used in combination with Dipyridamole.Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Dipyridamole.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Dipyridamole.Approved
FibrinolysinDipyridamole may increase the anticoagulant activities of Fibrinolysin.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Dipyridamole.Approved
FimasartanThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Fimasartan.Approved
FluconazoleThe serum concentration of Dipyridamole can be increased when it is combined with Fluconazole.Approved
FluindioneDipyridamole may increase the anticoagulant activities of Fluindione.Investigational
FluoxetineThe serum concentration of Dipyridamole can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Dipyridamole can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Dipyridamole can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Dipyridamole can be increased when it is combined with Flurazepam.Approved, Illicit
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Dipyridamole.Approved
FluvoxamineThe serum concentration of Dipyridamole can be increased when it is combined with Fluvoxamine.Approved, Investigational
FondaparinuxDipyridamole may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumDipyridamole may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Dipyridamole.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Dipyridamole.Approved, Vet Approved
GabexateDipyridamole may increase the anticoagulant activities of Gabexate.Investigational
GalantamineThe therapeutic efficacy of Galantamine can be decreased when used in combination with Dipyridamole.Approved
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be decreased when used in combination with Dipyridamole.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Dipyridamole.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Dipyridamole.Approved
GenisteinThe serum concentration of Dipyridamole can be increased when it is combined with Genistein.Investigational
Ginkgo bilobaThe therapeutic efficacy of Ginkgo biloba can be decreased when used in combination with Dipyridamole.Approved, Nutraceutical
GlucosamineGlucosamine may increase the antiplatelet activities of Dipyridamole.Approved
GlyburideThe serum concentration of Dipyridamole can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Dipyridamole can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Dipyridamole can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Dipyridamole.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Dipyridamole.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Guanfacine.Approved, Investigational
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Dipyridamole.Approved
HalothaneThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Halothane.Approved, Vet Approved
HeparinDipyridamole may increase the anticoagulant activities of Heparin.Approved, Investigational
HexobarbitalHexobarbital may increase the hypotensive activities of Dipyridamole.Approved
HigenamineDipyridamole may increase the anticoagulant activities of Higenamine.Investigational
HirulogDipyridamole may increase the anticoagulant activities of Hirulog.Experimental
Huperzine AThe therapeutic efficacy of Huperzine A can be decreased when used in combination with Dipyridamole.Investigational
HydralazineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Dipyridamole.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Hydroflumethiazide.Approved
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Dipyridamole.Approved
IbudilastIbudilast may increase the anticoagulant activities of Dipyridamole.Approved, Investigational
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Dipyridamole.Approved
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Dipyridamole.Approved, Nutraceutical
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Dipyridamole.Approved
idraparinuxDipyridamole may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Dipyridamole.Approved, Withdrawn
IloprostThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Iloprost.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Dipyridamole.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Dipyridamole.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Dipyridamole.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Dipyridamole.Approved
IndenololDipyridamole may increase the bradycardic activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Dipyridamole can be decreased when it is combined with Indinavir.Approved
IndobufenDipyridamole may increase the anticoagulant activities of Indobufen.Investigational
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Dipyridamole.Approved, Investigational
IndoraminThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Indoramin.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Dipyridamole.Approved, Investigational
IsavuconazoniumThe serum concentration of Dipyridamole can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Isoflurane.Approved, Vet Approved
IsoflurophateThe therapeutic efficacy of Isoflurophate can be decreased when used in combination with Dipyridamole.Approved, Withdrawn
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Dipyridamole.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Dipyridamole.Approved
ItraconazoleThe serum concentration of Dipyridamole can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Dipyridamole can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Dipyridamole.Approved, Vet Approved
Kct 0809Dipyridamole may increase the anticoagulant activities of Kct 0809.Investigational
KetamineThe serum concentration of Dipyridamole can be increased when it is combined with Ketamine.Approved, Vet Approved
KetanserinKetanserin may increase the anticoagulant activities of Dipyridamole.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Dipyridamole.Approved
KetoconazoleThe serum concentration of Dipyridamole can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolDipyridamole may increase the bradycardic activities of Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Lacidipine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Dipyridamole.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Dipyridamole.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Dipyridamole.Approved, Investigational
LapatinibThe serum concentration of Dipyridamole can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Dipyridamole.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Dipyridamole.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Dipyridamole.Approved
LepirudinDipyridamole may increase the anticoagulant activities of Lepirudin.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Lercanidipine.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Dipyridamole.Approved, Investigational
LevobunololDipyridamole may increase the bradycardic activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Levobupivacaine.Approved
LevodopaDipyridamole may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Dipyridamole.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Dipyridamole.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Levosimendan.Approved, Investigational
LevothyroxineThe serum concentration of Dipyridamole can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Dipyridamole can be increased when it is combined with Lidocaine.Approved, Vet Approved
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Dipyridamole.Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Dipyridamole.Approved
LiothyronineThe serum concentration of Dipyridamole can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Dipyridamole can be decreased when it is combined with Liotrix.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Dipyridamole.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Dipyridamole can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Dipyridamole.Approved
LopinavirThe serum concentration of Dipyridamole can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Dipyridamole can be increased when it is combined with Loratadine.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Dipyridamole.Approved
LovastatinThe serum concentration of Dipyridamole can be increased when it is combined with Lovastatin.Approved, Investigational
LumacaftorThe serum concentration of Dipyridamole can be decreased when it is combined with Lumacaftor.Approved
MalathionThe therapeutic efficacy of Malathion can be decreased when used in combination with Dipyridamole.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Dipyridamole.Approved, Investigational
MaprotilineThe serum concentration of Dipyridamole can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Dipyridamole can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dipyridamole.Approved
MefloquineThe therapeutic efficacy of Mefloquine can be decreased when used in combination with Dipyridamole.Approved
Megestrol acetateThe serum concentration of Dipyridamole can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MemantineThe therapeutic efficacy of Memantine can be decreased when used in combination with Dipyridamole.Approved, Investigational
MeprobamateThe serum concentration of Dipyridamole can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Mesalazine.Approved
MethadoneThe serum concentration of Dipyridamole can be increased when it is combined with Methadone.Approved
Methanesulfonyl FluorideThe therapeutic efficacy of Methanesulfonyl Fluoride can be decreased when used in combination with Dipyridamole.Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Dipyridamole.Approved
MethohexitalMethohexital may increase the hypotensive activities of Dipyridamole.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Dipyridamole.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dipyridamole.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Dipyridamole.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Dipyridamole.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Dipyridamole.Approved, Vet Approved
MetipranololDipyridamole may increase the bradycardic activities of Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Dipyridamole.Approved
MetoprololDipyridamole may increase the bradycardic activities of Metoprolol.Approved, Investigational
MibefradilThe serum concentration of Dipyridamole can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Dipyridamole can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Dipyridamole can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Dipyridamole can be decreased when it is combined with Mifepristone.Approved, Investigational
MilrinoneMilrinone may increase the anticoagulant activities of Dipyridamole.Approved
MinaprineThe therapeutic efficacy of Minaprine can be decreased when used in combination with Dipyridamole.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Dipyridamole.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Dipyridamole.Approved
MitomycinThe serum concentration of Dipyridamole can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Dipyridamole can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Dipyridamole.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Dipyridamole.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Moxonidine.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Dipyridamole.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Nabilone.Approved, Investigational
NadololDipyridamole may increase the bradycardic activities of Nadolol.Approved
NadroparinDipyridamole may increase the anticoagulant activities of Nadroparin.Approved
NafamostatDipyridamole may increase the anticoagulant activities of Nafamostat.Investigational
NaftopidilNaftopidil may increase the anticoagulant activities of Dipyridamole.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Dipyridamole.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Dipyridamole.Approved, Vet Approved
NaltrexoneThe serum concentration of Dipyridamole can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Dipyridamole can be increased when it is combined with Naringenin.Experimental
NCX 4016The risk or severity of adverse effects can be increased when Dipyridamole is combined with NCX 4016.Investigational
NebivololThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Dipyridamole can be decreased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Dipyridamole can be decreased when it is combined with Nelfinavir.Approved
NeostigmineThe therapeutic efficacy of Neostigmine can be decreased when used in combination with Dipyridamole.Approved, Vet Approved
NesiritideThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Nesiritide.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Dipyridamole.Approved
NicorandilNicorandil may increase the hypotensive activities of Dipyridamole.Approved
NifedipineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Nifedipine.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Dipyridamole.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Nilvadipine.Approved
NimesulideNimesulide may increase the anticoagulant activities of Dipyridamole.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Dipyridamole.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Dipyridamole.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Dipyridamole.Approved
NitrazepamThe serum concentration of Dipyridamole can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Dipyridamole can be increased when it is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Nitric Oxide.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Dipyridamole.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Dipyridamole.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Dipyridamole.Approved
NorethisteroneThe serum concentration of Dipyridamole can be decreased when it is combined with Norethisterone.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Obinutuzumab.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Dipyridamole.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Dipyridamole.Approved, Investigational
OlsalazineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Olsalazine.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Dipyridamole.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Dipyridamole.Approved
OmeprazoleThe serum concentration of Dipyridamole can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Dipyridamole.Approved
OtamixabanDipyridamole may increase the anticoagulant activities of Otamixaban.Investigational
OxprenololDipyridamole may increase the bradycardic activities of Oxprenolol.Approved
P-NitrophenolThe serum concentration of Dipyridamole can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Dipyridamole can be increased when it is combined with Paclitaxel.Approved, Vet Approved
Palmitic AcidThe serum concentration of Dipyridamole can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Dipyridamole.Approved, Investigational
PantoprazoleThe serum concentration of Dipyridamole can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Papaverine.Approved
ParnaparinDipyridamole may increase the anticoagulant activities of Parnaparin.Approved
ParoxetineThe serum concentration of Dipyridamole can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Dipyridamole.Approved
PenbutololDipyridamole may increase the bradycardic activities of Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Dipyridamole.Approved, Vet Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Dipyridamole.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Dipyridamole.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Dipyridamole.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Phenelzine.Approved
PhenindioneDipyridamole may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe serum concentration of Dipyridamole can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Phenoxybenzamine.Approved
PhenprocoumonDipyridamole may increase the anticoagulant activities of Phenprocoumon.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Phentolamine.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Dipyridamole.Approved, Vet Approved
PhysostigmineThe therapeutic efficacy of Physostigmine can be decreased when used in combination with Dipyridamole.Approved
PimozideThe serum concentration of Dipyridamole can be increased when it is combined with Pimozide.Approved
PindololDipyridamole may increase the bradycardic activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Pipamperone.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Dipyridamole.Approved
PlasminDipyridamole may increase the anticoagulant activities of Plasmin.Investigational
Platelet Activating FactorThe serum concentration of Dipyridamole can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Dipyridamole.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Dipyridamole.Approved
PosaconazoleThe serum concentration of Dipyridamole can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PractololDipyridamole may increase the bradycardic activities of Practolol.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Pramipexole.Approved, Investigational
PrasugrelDipyridamole may increase the anticoagulant activities of Prasugrel.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Dipyridamole.Approved
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Dipyridamole.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Dipyridamole.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Dipyridamole.Approved, Vet Approved
PrimidonePrimidone may increase the hypotensive activities of Dipyridamole.Approved, Vet Approved
ProbenecidThe serum concentration of Dipyridamole can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Dipyridamole can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Dipyridamole can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Dipyridamole can be increased when it is combined with Propafenone.Approved
PropofolThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Propofol.Approved, Investigational, Vet Approved
PropranololDipyridamole may increase the bradycardic activities of Propranolol.Approved, Investigational
Protein CDipyridamole may increase the anticoagulant activities of Protein C.Approved
Protein S humanDipyridamole may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeDipyridamole may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineThe serum concentration of Dipyridamole can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Dipyridamole.Approved
PyridostigmineThe therapeutic efficacy of Pyridostigmine can be decreased when used in combination with Dipyridamole.Approved
QuercetinThe serum concentration of Dipyridamole can be increased when it is combined with Quercetin.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Quetiapine.Approved
QuinacrineThe serum concentration of Dipyridamole can be increased when it is combined with Quinacrine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Dipyridamole.Approved, Investigational
QuinidineThe serum concentration of Dipyridamole can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Dipyridamole.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Dipyridamole.Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Dipyridamole.Approved
RanitidineThe serum concentration of Dipyridamole can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Dipyridamole.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Rasagiline.Approved
ReboxetineThe serum concentration of Dipyridamole can be increased when it is combined with Reboxetine.Approved, Investigational
RegadenosonThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Regadenoson.Approved
RegorafenibThe serum concentration of Dipyridamole can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Remifentanil.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dipyridamole.Approved
ResveratrolResveratrol may increase the anticoagulant activities of Dipyridamole.Experimental, Investigational
ReteplaseDipyridamole may increase the anticoagulant activities of Reteplase.Approved
ReviparinDipyridamole may increase the anticoagulant activities of Reviparin.Approved
RidogrelRidogrel may increase the anticoagulant activities of Dipyridamole.Approved
RifampicinThe serum concentration of Dipyridamole can be decreased when it is combined with Rifampicin.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Dipyridamole.Approved, Investigational
RilpivirineThe serum concentration of Dipyridamole can be increased when it is combined with Rilpivirine.Approved
RiociguatDipyridamole may increase the hypotensive activities of Riociguat.Approved
RisperidoneDipyridamole may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe serum concentration of Dipyridamole can be decreased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanDipyridamole may increase the anticoagulant activities of Rivaroxaban.Approved
RivastigmineThe therapeutic efficacy of Rivastigmine can be decreased when used in combination with Dipyridamole.Approved, Investigational
RolapitantThe serum concentration of Dipyridamole can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Dipyridamole.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Ropivacaine.Approved
RosiglitazoneDipyridamole may increase the anticoagulant activities of Rosiglitazone.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Sacubitril.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Salicylic acid.Approved, Vet Approved
SaquinavirThe serum concentration of Dipyridamole can be decreased when it is combined with Saquinavir.Approved, Investigational
SCH-530348SCH-530348 may increase the anticoagulant activities of Dipyridamole.Investigational
ScopolamineThe serum concentration of Dipyridamole can be increased when it is combined with Scopolamine.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Dipyridamole.Approved, Vet Approved
SelegilineThe serum concentration of Dipyridamole can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Dipyridamole.Approved
SertralineThe serum concentration of Dipyridamole can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Sevoflurane.Approved, Vet Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Dipyridamole.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Dipyridamole.Approved
SimvastatinThe serum concentration of Dipyridamole can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Dipyridamole can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Dipyridamole.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Sodium Nitrite.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Dipyridamole.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Dipyridamole.Approved, Investigational
SotalolDipyridamole may increase the bradycardic activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Dipyridamole.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Dipyridamole.Experimental
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Dipyridamole.Approved
SRT501SRT501 may increase the anticoagulant activities of Dipyridamole.Investigational
St. John's WortThe serum concentration of Dipyridamole can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Dipyridamole can be increased when it is combined with Staurosporine.Experimental
StreptokinaseThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Streptokinase.Approved
StreptozocinThe serum concentration of Dipyridamole can be decreased when it is combined with Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Sufentanil.Approved, Investigational
SulfinpyrazoneThe serum concentration of Dipyridamole can be increased when it is combined with Sulfinpyrazone.Approved
SulodexideDipyridamole may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SumatriptanThe serum concentration of Dipyridamole can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Dipyridamole can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe therapeutic efficacy of Tacrine can be decreased when used in combination with Dipyridamole.Withdrawn
TacrolimusThe serum concentration of Dipyridamole can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Dipyridamole can be decreased when it is combined with Tamoxifen.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Tamsulosin.Approved, Investigational
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Dipyridamole.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Dipyridamole.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Dipyridamole.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Dipyridamole.Approved, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Dipyridamole.Approved
TenecteplaseDipyridamole may increase the anticoagulant activities of Tenecteplase.Approved
TerazosinThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Terazosin.Approved
TerfenadineThe serum concentration of Dipyridamole can be increased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Dipyridamole can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Dipyridamole can be increased when it is combined with Testosterone.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Dipyridamole.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Dipyridamole.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Thioridazine.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Dipyridamole.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Dipyridamole.Approved
TimololDipyridamole may increase the bradycardic activities of Timolol.Approved
TinzaparinDipyridamole may increase the anticoagulant activities of Tinzaparin.Approved
TipranavirTipranavir may increase the antiplatelet activities of Dipyridamole.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Dipyridamole.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dipyridamole.Approved
TolazolineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Tolcapone.Approved, Withdrawn
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Dipyridamole.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Dipyridamole.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Dipyridamole.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Dipyridamole.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Tositumomab.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Dipyridamole.Approved
TranilastTranilast may increase the anticoagulant activities of Dipyridamole.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Tranylcypromine.Approved
TrapidilTrapidil may increase the anticoagulant activities of Dipyridamole.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Dipyridamole.Approved
TrazodoneThe serum concentration of Dipyridamole can be decreased when it is combined with Trazodone.Approved, Investigational
TreprostinilTreprostinil may increase the antiplatelet activities of Dipyridamole.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Dipyridamole.Approved
TrichlorfonThe therapeutic efficacy of Trichlorfon can be decreased when used in combination with Dipyridamole.Vet Approved
TrifluoperazineThe serum concentration of Dipyridamole can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Dipyridamole can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TriflusalDipyridamole may increase the anticoagulant activities of Triflusal.Approved
TrimethoprimThe serum concentration of Dipyridamole can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Dipyridamole can be increased when it is combined with Trimipramine.Approved
TroleandomycinThe serum concentration of Dipyridamole can be increased when it is combined with Troleandomycin.Approved
TubocurarineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Dipyridamole.Approved
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Dipyridamole.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Dipyridamole.Approved
UrokinaseDipyridamole may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Dipyridamole.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Dipyridamole.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Dipyridamole.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Dipyridamole.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Dipyridamole.Approved
VinblastineThe serum concentration of Dipyridamole can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Dipyridamole.Approved, Investigational
VincristineThe serum concentration of Dipyridamole can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Dipyridamole can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Dipyridamole.Approved
Vitamin EVitamin E may increase the antiplatelet activities of Dipyridamole.Approved, Nutraceutical, Vet Approved
VorapaxarDipyridamole may increase the anticoagulant activities of Vorapaxar.Approved
WarfarinDipyridamole may increase the anticoagulant activities of Warfarin.Approved
XimelagatranDipyridamole may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Dipyridamole may increase the anticoagulant activities of Ym150.Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Dipyridamole.Approved
ZimelidineThe serum concentration of Dipyridamole can be increased when it is combined with Zimelidine.Withdrawn
Food Interactions
  • Coffee and tea can decrease the effect of dipyridamole.
  • Take with food to reduce irritation.
References
Synthesis Reference

Minutza Leibovici, Itamar Kanari, Michael Fox, “Dipyridamole extended-release formulations and process for preparing same.” U.S. Patent US20070184110, issued August 09, 2007.

US20070184110
General References
  1. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996 Nov;143(1-2):1-13. [PubMed:8981292 ]
External Links
ATC CodesB01AC07
AHFS Codes
  • 24:12.92
PDB EntriesNot Available
FDA labelDownload (48.7 KB)
MSDSDownload (73.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9917
Blood Brain Barrier-0.6246
Caco-2 permeable-0.7261
P-glycoprotein substrateSubstrate0.7696
P-glycoprotein inhibitor INon-inhibitor0.5321
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.615
CYP450 2C9 substrateNon-substrate0.8345
CYP450 2D6 substrateNon-substrate0.6825
CYP450 3A4 substrateNon-substrate0.6849
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorInhibitor0.8045
CYP450 2D6 inhibitorInhibitor0.7201
CYP450 2C19 inhibitorNon-inhibitor0.957
CYP450 3A4 inhibitorInhibitor0.6789
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7806
Ames testNon AMES toxic0.7009
CarcinogenicityNon-carcinogens0.8884
BiodegradationNot ready biodegradable0.988
Rat acute toxicity2.1167 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5271
hERG inhibition (predictor II)Non-inhibitor0.633
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • App pharmaceuticals llc
  • Baxter healthcare corp anesthesia and critical care
  • Bedford laboratories div ben venue laboratories inc
  • Claris lifesciences ltd
  • Hospira inc
  • Teva parenteral medicines inc
  • Boehringer ingelheim pharmaceuticals inc
  • Actavis totowa llc
  • Barr laboratories inc
  • Glenmark generics inc usa
  • Impax laboratories inc
  • Lannett holdings inc
  • Murty pharmaceuticals inc
  • Purepac pharmaceutical co
  • Sandoz inc
  • Watson laboratories inc
  • Zydus pharmaceuticals usa inc
  • Boehringer Ingelheim Pharmaceuticals, Inc
Packagers
Dosage forms
FormRouteStrength
Capsule; capsule, extended releaseOral
TabletOral25 mg
TabletOral50 mg
TabletOral75 mg
CapsuleOral
Capsule, extended releaseOral
InjectionIntravenous5 mg/mL
Injection, solutionIntravenous5 mg/mL
SolutionIntravenous5 mg/mL
TabletOral25 mg/1
TabletOral50 mg/1
TabletOral75 mg/1
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral50 mg/1
Tablet, film coatedOral75 mg/1
LiquidIntravenous5 mg
TabletOral100 mg
SolutionIntravenous5 mg
Tablet, coatedOral25 mg/1
Tablet, coatedOral50 mg/1
Tablet, coatedOral75 mg/1
Prices
Unit descriptionCostUnit
Dipyridamole powder5.34USD g
Aggrenox capsule sa3.25USD capsule
Aggrenox 25-200 mg 12 Hour Capsule3.0USD capsule
Dipyridamole 5 mg/ml ampul1.5USD ml
Persantine 75 mg tablet1.46USD tablet
Dipyridamole 5 mg/ml vial1.32USD ml
Dipyridamole 75 mg tablet1.28USD tablet
Persantine 50 mg tablet1.09USD tablet
Dipyridamole 50 mg tablet0.96USD tablet
Persantine 25 mg tablet0.89USD tablet
Dipyridamole 25 mg tablet0.58USD tablet
Apo-Dipyridamole (Fc) 75 mg Tablet0.46USD tablet
Apo-Dipyridamole (Fc) 50 mg Tablet0.31USD tablet
Apo-Dipyridamole (Fc) 25 mg Tablet0.28USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6015577 No1997-01-182017-01-18Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point163 °CPhysProp
water solubilitySlightlyNot Available
logP1.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.922 mg/mLALOGPS
logP1.52ALOGPS
logP1.81ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)14.97ChemAxon
pKa (Strongest Basic)6.59ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area145.44 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity142.78 m3·mol-1ChemAxon
Polarizability56.94 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dialkylarylamines. These are aliphatic aromatic amines in which the amino group is linked to two aliphatic chains and one aromatic group.
KingdomOrganic compounds
Super ClassOrganonitrogen compounds
ClassAmines
Sub ClassTertiary amines
Direct ParentDialkylarylamines
Alternative Parents
Substituents
  • Dialkylarylamine
  • Aminopyrimidine
  • Imidolactam
  • Pyrimidine
  • Piperidine
  • Heteroaromatic compound
  • Azacycle
  • Organoheterocyclic compound
  • Alkanolamine
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. Can hydrolyze both cAMP and cGMP, but has higher affinity for cAMP and is more efficient with cAMP as substrate.
Gene Name:
PDE10A
Uniprot ID:
Q9Y233
Molecular Weight:
88411.71 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Fujishige K, Kotera J, Michibata H, Yuasa K, Takebayashi S, Okumura K, Omori K: Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem. 1999 Jun 25;274(26):18438-45. [PubMed:10373451 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. This phosphodiesterase catalyzes the specific hydrolysis of cGMP to 5'-GMP (PubMed:9714779, PubMed:15489334). Specifically regulates nitric-oxide-generated cGMP (PubMed:15489334).
Gene Name:
PDE5A
Uniprot ID:
O76074
Molecular Weight:
99984.14 Da
References
  1. Kulkarni SK, Patil CS: Phosphodiesterase 5 enzyme and its inhibitors: update on pharmacological and therapeutical aspects. Methods Find Exp Clin Pharmacol. 2004 Dec;26(10):789-99. [PubMed:15672122 ]
  2. Santini F, Casali G, Franchi G, Auriemma S, Lusini M, Barozzi L, Favaro A, Messina A, Mazzucco A: Hemodynamic effects of inhaled nitric oxide and phosphodiesterase inhibitor (dipyridamole) on secondary pulmonary hypertension following heart valve surgery in adults. Int J Cardiol. 2005 Aug 18;103(2):156-63. [PubMed:16080974 ]
  3. Kruuse C, Lassen LH, Iversen HK, Oestergaard S, Olesen J: Dipyridamole may induce migraine in patients with migraine without aura. Cephalalgia. 2006 Aug;26(8):925-33. [PubMed:16886928 ]
  4. Jackson EK, Ren J, Zacharia LC, Mi Z: Characterization of renal ecto-phosphodiesterase. J Pharmacol Exp Ther. 2007 May;321(2):810-5. Epub 2007 Feb 16. [PubMed:17308037 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
Gene Name:
PDE4A
Uniprot ID:
P27815
Molecular Weight:
98142.155 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Catalyzes the hydrolytic deamination of adenosine and 2-deoxyadenosine. Plays an important role in purine metabolism and in adenosine homeostasis. Modulates signaling by extracellular adenosine, and so contributes indirectly to cellular signaling events. Acts as a positive regulator of T-cell coactivation, by binding DPP4. Its interaction with DPP4 regulates lymphocyte-epithelial cell adhesion.
Gene Name:
ADA
Uniprot ID:
P00813
Molecular Weight:
40764.13 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
May be an organic anion pump relevant to cellular detoxification.
Gene Name:
ABCC4
Uniprot ID:
O15439
Molecular Weight:
149525.33 Da
References
  1. van Aubel RA, Smeets PH, Peters JG, Bindels RJ, Russel FG: The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol. 2002 Mar;13(3):595-603. [PubMed:11856762 ]
  2. Reid G, Wielinga P, Zelcer N, De Haas M, Van Deemter L, Wijnholds J, Balzarini J, Borst P: Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol. 2003 May;63(5):1094-103. [PubMed:12695538 ]
  3. Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, Keppler D: Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology. 2003 Aug;38(2):374-84. [PubMed:12883481 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Acts as a multispecific organic anion pump which can transport nucleotide analogs.
Gene Name:
ABCC5
Uniprot ID:
O15440
Molecular Weight:
160658.8 Da
References
  1. Reid G, Wielinga P, Zelcer N, De Haas M, Van Deemter L, Wijnholds J, Balzarini J, Borst P: Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol. 2003 May;63(5):1094-103. [PubMed:12695538 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
  2. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 02:37